

Sheet 1 of 3


SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50125/044001
	Serial No.	10/031,313
	Applicant	Hallek et al.
	Filing Date	June 3, 2002
	Group	1648
	IDS Filed	January 18, 2007

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
/SBC/	2001/031463	10/18/01	Kleinschmidt et al.
/SBC/	2002/0192823	12/19/02	Bartlett et al.
/SBC/	5,276,136	01/04/94	Skubitz et al.
/SBC/	6,491,907	12/10/02	Rabinowitz et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/SBC/	Anderson, "Human Gene Therapy," <i>Nature</i> 392:25-30 (1998).
	Asokan et al., "AAV Does the Shuffle," <i>Nature Biotechnology</i> 24:158-160 (2006).
	Buning et al., "Receptor Targeting of Adeno-Associated Virus Vectors," <i>Gene Therapy</i> 10:1142-1151 (2003).
	Grifman et al., "Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-Associated Virus Capsids," <i>Molecular Therapy</i> 3:964-975 (2001).
	Hoque et al., "Nuclear Transport of the Major Capsid Protein is Essential for Adeno-Associated Virus Capsid Formation," <i>Journal of Virology</i> 73:7912-7915 (1999).
	Huttner et al., "Genetic Modifications of the Adeno-Associated Virus Type 2 Capsid Reduce the Affinity and the Neutralizing Effects of Human Serum Antibodies," <i>Gene Therapy</i> 10:2139-2147 (2003).
	Kmieciak, "Gene Therapy," <i>American Scientist</i> 87:240-247 (1999).

EXAMINER /Stacy B. Chen/	DATE CONSIDERED 03/26/2007
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50125/044001
	Serial No.	10/031,313
	Applicant	Hallek et al.
	Filing Date	June 3, 2002
	Group	1648
	IDS Filed	January 18, 2007

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/SBC/	Maass et al., "Recombinant Adeno-Associated Virus for the Generation of Autologous, Gene-Modified Tumor Vaccines: Evidence for a High Transduction Efficiency into Primary Epithelial Cancer Cells," <i>Human Gene Therapy</i> 9:1049-1059 (1998).
	Maheshri et al., "Directed Evolution of Adeno-Associated Virus Yields Enhanced Gene Delivery Vectors," <i>Nature Biotechnology</i> 24:198-204 (2006).
	Marshall, "Second Child in French Trial is Found to Have Leukemia," <i>Science</i> 299:320 (2003).
	Meng et al., "Tumor Suppressor Genes as Targets for Cancer Gene Therapy," <i>Gene Therapy of Cancer Chapter 1</i> , pp. 3-18 (1999).
	Mizukami et al., "Adeno-Associated Virus Type 2 Binds to a 150-Kilodalton Cell Membrane Glycoprotein," <i>Virology</i> 217:124-130 (1996).
	Moskalenko et al., "Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure," <i>Journal of Virology</i> 74:1761-1766 (2000).
	Nicklin et al., "Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial Cells," <i>Molecular Therapy</i> 4:174-181 (2001).
	Perabo et al., "In Vitro Selection of Viral Vectors with Modified Tropism: The Adeno-Associated Virus Display," <i>Molecular Therapy</i> 8:151-157 (2003).
	Qing et al., "Human Fibroblast Growth Factor Receptor 1 is a Co-Receptor for Infection by Adeno-Associated Virus 2," <i>Nature Medicine</i> 5:71-77 (1999).
	Ried et al., "Adeno-Associated Virus Capsids Displaying Immunoglobulin-Binding Domains Permit Antibody-Mediated Vector Retargeting to Specific Cell Surface Receptors," <i>Journal of Virology</i> 76:4559-4566 (2002).
	Russell, "Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects," <i>European Journal of Cancer</i> 30A:1165-1171 (1994).
	Shi et al., "Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface Receptors," <i>Human Gene Therapy</i> 12:1697-1711 (2001).
	Shi et al., "RGD Inclusion of VP3 Provides Adeno-Associated Virus Type 2 (AAV2)-Based Vectors with a Heparan Sulfate-Independent Cell Entry Mechanism," <i>Molecular Therapy</i> 7:515-525 (2003).
	Smith et al., "The Challenges of genome Sequence Annotation or 'the Devil is in the Details'," <i>Nature Biotechnology</i> , 15:1222-1223 (1997).
	Spear et al., "Evidence for Two Nucleotide Sequence Orientations Within the Terminal Repetition of Adeno-Associated Virus DNA," <i>Journal of Virology</i> 24:627-634 (1977).
✓	Starovasnik et al., "Structural Mimicry of a Native Protein by a Minimized Binding Domain," <i>Proc. Natl. Acad. Sci.</i>

EXAMINER /Stacy B. Chen/

DATE CONSIDERED 03/26/2007

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

Sheet 3 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50125/044001
	Serial No.	10/031,313
	Applicant	Hallek et al.
	Filing Date	June 3, 2002
	Group	1648
	IDS Filed	January 18, 2007

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	USA 94:10080-10085 (1997).
/SBC/	Summerford et al., "Membrane Associated Heparan Sulfate Proteoglycan is a Receptor for Adeno-Associated Virus Type 2 Virions," <i>Journal of Virology</i> 72:1438-1445 (1998).
	Summerford et al., "αVβ5 Integrin: A Co-receptor for Adeno-Associated Virus Type 2 Infection," <i>Nature Medicine</i> 5:78-82 (1999).
	Tseng et al., "Evolutionary Model for Predicting Protein Function by Matching Local Surfaces: a Bayesian Monte Carlo Approach," The Ninth Annual Conference on Research in Computational Molecular Biology, May 14-18, 2005
	Verma et al., "Gene Therapy-Promises, Problems and Prospects," <i>Nature</i> 389:239-242 (1997).
	Wendtner et al., "Efficient Gene Transfer of CD40 Ligand into Primary B-CLL cells using recombinant Adeno-Associated Virus (rAAV) Vectors," <i>Blood</i> 100:1655-1661 (2002).
	White et al., "'Designer' Gene Therapy May Target Specific Body Area," <i>Business News</i> 2:1-2 (2003).
	White et al., "Targeted Gene Delivery to Vascular Tissue in Vivo by Tropism-Modified Adeno-Associated Virus Vectors," <i>Circulation</i> 109:513-519 (2004).
	Wobus et al., "Monoclonal Antibodies Against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2-Cell Interaction and Neutralization of AAV-2 Infection," <i>Journal of Virology</i> 74:9281-9293 (2000).
↓	Wu et al., "Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism," <i>Journal of Virology</i> 74:8635-8647 (2000).

EXAMINER /Stacy B. Chen/	DATE CONSIDERED 03/26/2007
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	